본문으로 건너뛰기
← 뒤로

Clinical and biological predictors of treatment-free remission in CML.

1/5 보강
Leukemia & lymphoma 📖 저널 OA 9.2% 2022: 1/1 OA 2025: 2/55 OA 2026: 15/137 OA 2022~2026 2025 Vol.66(14) p. 2578-2587
Retraction 확인
출처

Sutton E, Shanmuganathan N, Ross D

📝 환자 설명용 한 줄

Chronic Myeloid Leukemia (CML) is characterized by the Philadelphia chromosome t(9:22) and results in the fusion gene.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Sutton E, Shanmuganathan N, Ross D (2025). Clinical and biological predictors of treatment-free remission in CML.. Leukemia & lymphoma, 66(14), 2578-2587. https://doi.org/10.1080/10428194.2025.2560081
MLA Sutton E, et al.. "Clinical and biological predictors of treatment-free remission in CML.." Leukemia & lymphoma, vol. 66, no. 14, 2025, pp. 2578-2587.
PMID 41070556 ↗

Abstract

Chronic Myeloid Leukemia (CML) is characterized by the Philadelphia chromosome t(9:22) and results in the fusion gene. Since the evolution of targeted therapy in the form of tyrosine kinase inhibitors (TKIs), overall survival has improved to 94% at 5 years. Early studies identified that approximately half of patients could maintain a major molecular remission (MMR), i.e.  ≤ 0.1%, in the absence of TKI therapy. This is termed treatment-free remission (TFR). Identifying clinical and biological predictors of TFR has become a major goal in CML. In this review, we discuss clinical predictors of TFR, including features at diagnosis, molecular response and kinetics, depth and duration of molecular response, and dose reduction prior to TKI cessation in determining TFR success. We also discuss advances in highly sensitive Minimal Residual Disease (MRD) assays, consider the genomic profile of CML patients and review the role of the immune environment in sustaining TFR.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반